$ATLX

Fogassa Marc sold (to issuer) $86K of ATLX

Fogassa Marc (Chief Executive Officer) sold (to issuer) 28,663 shares of Atlas Lithium Corp (ATLX) at an average of $3.01 ($3.01–$3.02) across 2 trades over 2026-07-22 to 2026-07-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fogassa Marc
Published Jul 25, 2026, 1:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 25, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATLX
Neutral
high confidence
Mentioned
$ATLX
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATLXNeutralLow
01

Why it matters

The disclosure updates the insider’s post-transaction holdings but does not introduce new company performance, guidance, or regulatory information.

02

Market read

Primarily a sentiment/positioning datapoint for ATLX, with low expected impact absent additional catalysts.

03

What to watch

The transaction is a sale to the issuer and the article provides no follow-on context (e.g., other insider buys, financing needs, or changes in guidance), limiting fundamental inference.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-24 after trades on 2026-07-22 to 2026-07-23.

Background

The article is an SEC Form 4 insider transaction disclosure for Atlas Lithium, reported as a sale to the issuer by the CEO under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ATLXNeutralHigh confidence
Context

Atlas Lithium CEO Marc Fogassa sold 28,663 shares to the issuer at about $3.0135 per share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it specifies a pre-arranged 10b5-1 plan and a sale to the issuer, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal sector read-through; this is company-specific insider trading with no operational or regulatory disclosure.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal liquidity needs; traders may still treat it as a mild negative sentiment datapoint.

Key entities

  • Atlas Lithium Corp

    Subject of the Form 4 insider transaction disclosure.

  • Fogassa Marc

    CEO and director, reported sale to the issuer under a 10b5-1 plan.

Related articles

$ATLXMed

Atlas Lithium Receives Strong Product Demand; On Track for Commercial Production in 2027

Atlas Lithium (NASDAQ: ATLX) said its 100%-owned Neves Project is on track for first commercial production of lithium oxide concentrate in Q4 2027. The company plans about 150,000 tonnes per year and reported written product interest totaling over 3x capacity. It cited DFS economics of 145% after-tax IRR, 11-month payback, and $489 per tonne operating costs.

$ATLXMed

Atlas Lithium (NASDAQ: ATLX) said its 100% owned Neves Project in Brazil is on track for first commercial production of lithium oxide concentrate in Q4 2027

Atlas Lithium (NASDAQ: ATLX) said its 100% owned Neves Project in Brazil is on track for first commercial production of lithium oxide concentrate in Q4 2027. The company targets about 150,000 tonnes per year and reports written product interest totaling over three times capacity. It cites DFS economics of 145% after-tax IRR and 11-month payback, with operating costs of $489 per tonne.